Therapeutic Advances in Vaccines and Immunotherapy

Journal Highlights

• Launched in 2013
• Gold open access journal – all articles are made freely available online immediately upon publication
• Rigorous peer review
• Listed in PubMed
  

Therapeutic Advances in Vaccines and Immunotherapy is a peer-reviewed open access journal which focuses on all areas of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as an ever-growing repertoire of other immunotherapeutic interventions. Please see the aims and scope for further information.

Diversity, Equity and Inclusion Statement

Therapeutic Advances in Vaccines and Immunotherapy promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the research community.

Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.

We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.

We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.

Submission information

Submit your manuscript today at https://mc.manuscriptcentral.com/tav.

Please see the submission guidelines tab for more information on how to submit your article to the journal.

Open access information

The article processing charge (APC) is $3,000 USD, currently discounted to a rate of $1,500 USD. The APC for a Plain Language Summary is $5,000 USD.

Contact

Please direct any queries to tavaccines@sagepub.co.uk

This journal changed its publication mode from subscription to open access in 2019.